

Name of the issue **Nephrocare Health Services Limited**

- 1. Type of issue (IPO/ FPO)** IPO
- 2. Issue size (Rs. crore)** **871.05**
Source: Prospectus dated December 12, 2025
- 3. Grade of issue along with name of the rating agency** NA
- 4. Subscription level (number of times)** 14.00 times
Note: (After removing multiple and duplicate bids and technical rejection case and excluding Anchor)
Source: Minutes for Basis of Allotment as finalized dated December 15, 2025
- 5. QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges**
- | | | |
|--|------------|--------|
| (i) allotment in the issue ⁽¹⁾ | 16.12.2025 | 9.21% |
| (ii) at the end of the 1 st Quarter immediately after the listing | 31.12.2025 | 17.41% |
| (iii) at the end of 1 st FY* | 31.03.2026 | NA |
| (iv) at the end of 2 nd FY* | 31.03.2027 | NA |
| (v) at the end of 3 rd FY* | 31.03.2028 | NA |

⁽¹⁾ Source: Basis of Allotment. Includes allotment to Anchor Investors
 *QIB Holding not available as reporting for the relevant years has not been completed.

6. Consolidated Financials of the issuer

(Rs. in crore)

Parameters	FY25-26*	FY26-27*	FY27-28*
Income from operations	NA	NA	NA
Net Profit for the period	NA	NA	NA
Paid-up equity share capital	NA	NA	NA
Reserves excluding revaluation reserves	NA	NA	NA

*Financials not available as reporting for the relevant years has not been completed.

7. Trading status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE")

- | | |
|--|----|
| (i) at the end of 1 st FY (March 31, 2026)* | NA |
| (ii) at the end of 2 nd FY (March 31, 2027)* | NA |
| (iii) at the end of 3 rd FY (March 31, 2028)* | NA |

*Trading data not available as reporting for the relevant years has not been completed.

8. Change, if any, in directors of issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
at the end of March 31, 2026*	NA	NA
at the end of March 31, 2027*	NA	NA
at the end of March 31, 2028*	NA	NA

*Changes in Directors of Issuer not updated as the relevant financial years have not been completed

9. Status of implementation of project / commencement of commercial production

Particulars	Status
(i) as disclosed in the offer document	NA
(ii) Actual implementation	NA
(iii) Reasons for delay in implementation, if any	NA

10. Status of utilization of issue proceeds

(i) as disclosed in the offer document

(Rs. in crore)

Particulars	Estimated Amount to be funded from Net Proceeds	Estimated Amount to be funded from the Net Proceeds (Fiscal 2026)	Estimated Amount to be funded from the Net Proceeds (Fiscal 2027)	Estimated Amount to be funded from the Net Proceeds (Fiscal 2028)
Capital expenditure by our Company for opening new dialysis clinics in India	129.11	13.15	57.98	57.98
Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by our Company	136.00	136.00	–	–
General corporate purposes	60.05	6.67	26.69	26.69
Total	325.15	158.82	84.67	84.67

Source: Prospectus dated December 12, 2025

(ii) Actual utilization (as at Dec 30, 2025)

(Rs. in million)

Particulars	Actual Utilisation of Net Proceeds ⁽¹⁾
Capital expenditure by our Company for opening new dialysis clinics in India	NA
Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by our Company	
General corporate purposes	
Total	

(1) will be updated in due course

(iii) Reasons for deviation, if any

NA

11. Comments of monitoring agency, if applicable⁽¹⁾

- (a) Comments on use of funds NA
- (b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document NA
- (c) Any other reservations expressed by the monitoring agency about the end use of funds NA

(1) will be updated in due course

12. Price-related data

Designated SE
Issue Price (Rs.)
Listing Date

NSE Limited
Rs. 460.00/ share
December 17, 2025

Price parameters	At close of listing day	At close of 30 th calendar day from listing day	At close of 90 th calendar day from listing day**	As at the end of March 31, 2026**		
				Closing price	High	Low
Market Price*	471.25	505.25	–	–	–	–
NSE NIFTY 50	25,818.55	25,694.35	–	–	–	–

Sectoral Index	NA	NA	NA	NA	NA	NA
----------------	----	----	----	----	----	----

Price parameters	Closing price	As at the end of March 31, 2027**		As at the end of March 31, 2028**		
		High	Low	Closing price	High	Low
Market Price*	–	–	–	–	–	–
Sensex 30	–	–	–	–	–	–
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: Stock Exchange data. Where the 30th day / 90th day / March 31 of a particular year falls on a holiday, the immediately preceding trading day has been considered

* Market price on NSE taken, being the designated stock exchange

** Data not updated as the relevant financial years have not been completed

13. Basis for Issue Price and Comparison with Peer Group & Industry Average

Accounting ratio	Name of company	As disclosed in the offer document ⁽¹⁾ As at March 31, 2025	At the end of 1 st FY March 31, 2026	At the end of 2 nd FY March 31, 2027	At the end of 3 rd FY March 31, 2028
EPS (Basic)	Issuer: Restated Consolidated Financial Information	8.28	NA	NA	NA
	Peer Group:				
	Narayana Health	38.9	NA	NA	NA
	Jupiter Life Line Hospitals	29.47	NA	NA	NA
	Rainbow Children Hospital	23.97	NA	NA	NA
	Dr. Agarwal's Healthcare	2.8	NA	NA	NA
	Dr. Lal Path Labs	58.48	NA	NA	NA
	Metropolis Healthcare	28.29	NA	NA	NA
	Vijaya Diagnostics	13.95	NA	NA	NA
	Industry Avg	27.98	NA	NA	NA
EPS (Dilluted)	Issuer: Restated Consolidated Financial Information	8.01	NA	NA	NA
	Peer Group:				
	Narayana Health	38.9	NA	NA	NA
	Jupiter Life Line Hospitals	29.47	NA	NA	NA
	Rainbow Children Hospital	23.84	NA	NA	NA
	Dr. Agarwal's Healthcare	2.78	NA	NA	NA
	Dr. Lal Path Labs	58.4	NA	NA	NA
	Metropolis Healthcare	28.15	NA	NA	NA
	Vijaya Diagnostics	13.92	NA	NA	NA
	Industry Avg	27.92	NA	NA	NA
P/E	Issuer: Restated Consolidated Financial Information	NA	NA	NA	NA
	Peer Group:				
	Narayana Health	45.21	NA	NA	NA
	Jupiter Life Line Hospitals	51.1	NA	NA	NA
	Rainbow Children Hospital	56.84	NA	NA	NA
	Dr. Agarwal's Healthcare	179.42	NA	NA	NA
	Dr. Lal Path Labs	52.47	NA	NA	NA
Metropolis Healthcare	69.48	NA	NA	NA	

	Vijaya Diagnostics	73.14	NA	NA	NA
	Industry Avg	75.38	NA	NA	NA
RoNW%	Issuer: Restated Consolidated Financial Information	13.19%	NA	NA	NA
	Peer Group:				
	Narayana Health	21.77%	NA	NA	NA
	Jupiter Life Line Hospitals	14.27%	NA	NA	NA
	Rainbow Children Hospital	16.56%	NA	NA	NA
	Dr. Agarwal's Healthcare	5.73%	NA	NA	NA
	Dr. Lal Path Labs	22.30%	NA	NA	NA
	Metropolis Healthcare	10.90%	NA	NA	NA
	Vijaya Diagnostics	17.99%	NA	NA	NA
	Industry Avg	15.65%	NA	NA	NA
NAV per share	Issuer: Restated Consolidated Financial Information	59.56	NA	NA	NA
	Peer Group:				
	Narayana Health	160.35	NA	NA	NA
	Jupiter Life Line Hospitals	192.55	NA	NA	NA
	Rainbow Children Hospital	134.69	NA	NA	NA
	Dr. Agarwal's Healthcare	55.13	NA	NA	NA
	Dr. Lal Path Labs	245.26	NA	NA	NA
	Metropolis Healthcare	236.34	NA	NA	NA
	Vijaya Diagnostics	70.98	NA	NA	NA
	Industry Avg	156.47	NA	NA	NA

(1) Sourced from Prospectus dated December 12, 2025

14. Any other material information

NA

For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com